← Product Code [LON](/submissions/MI/subpart-b%E2%80%94diagnostic-devices/LON) · K050076 # VITEK 2 GRAM POSITIVE ERTAPENEM (K050076) _bioMerieux, Inc. · LON · Feb 18, 2005 · Microbiology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-b%E2%80%94diagnostic-devices/LON/K050076 ## Device Facts - **Applicant:** bioMerieux, Inc. - **Product Code:** [LON](/submissions/MI/subpart-b%E2%80%94diagnostic-devices/LON.md) - **Decision Date:** Feb 18, 2005 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 866.1645 - **Device Class:** Class 2 - **Review Panel:** Microbiology - **Attributes:** AI/ML ## Intended Use The VITEK®2 Antimicrobial Susceptibility Test is intended to be used with the VITEK®2 System for the automated quantitative or qualitative susceptibility testing of isolated colonies for most clinically significant aerobic gram-negative bacilli, Staphylococcus spp., Enterococcus spp., Streptococcus agalactiae, and S. pneumoniae. The VITEK®2 Gram Positive Susceptibility Card is intended for use with the VITEK®2 system in clinical laboratories as an in vitro test to determine the susceptibility of Staphylococcus spp., Enterococcus spp. and S. agalactiae to antimicrobial agents when used as instructed in the Online Product Information. ## Device Story VITEK®2 system performs automated antimicrobial susceptibility testing (AST) on isolated bacterial colonies. Input: bacterial suspension in saline (standardized to McFarland 0.5 via DensiChek) loaded into 64-well test cards. Operation: instrument automatically dilutes suspension, vacuum-fills cards, seals them, and incubates at 35.5°C. Optical sensors perform periodic light transmittance readings every 15 minutes to monitor growth. Output: MIC values and category interpretations (Susceptible/Resistant). Used in clinical laboratories by trained personnel. Results assist clinicians in selecting appropriate antibiotic therapy for patients with bacterial infections. ## Clinical Evidence Performance was evaluated using fresh and stock clinical isolates and stock challenge strains. The device demonstrated acceptable category agreement when compared to the NCCLS reference agar dilution method. No specific sensitivity/specificity metrics were provided in the summary. ## Technological Characteristics Miniaturized broth microdilution AST card; automated incubation and optical growth monitoring; utilizes VITEK 2 System; qualitative test for Ertapenem (≤0.5 - ≥8 µg/ml). ## Regulatory Identification A fully automated short-term incubation cycle antimicrobial susceptibility system is a device that incorporates concentrations of antimicrobial agents into a system for the purpose of determining in vitro susceptibility of bacterial pathogens isolated from clinical specimens. Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases. ## Special Controls *Classification.* Class II (special controls). The special control for this device is FDA's guidance document entitled “Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA.” ## Predicate Devices - VITEK®2 Gram Positive Susceptibility Card for Gatifloxacin (k032314) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ K050076 Image /page/0/Picture/1 description: The image shows the date "FEB 1 8 2005" on the left side. To the right of the date is the word "BIOMERIEUX". There is a black circle with a line through it above the word "BIOMERIEUX". ## 510(k) SUMMARY ### VITEK® 2 Gram Positive Ertapenem #### 510(k) Submission Information: | Submitter's Name: | bioMérieux, Inc. | |----------------------|--------------------------------------------------------------------------------------------------------| | Address: | 595 Anglum Road
Hazelwood, MO 63042 | | Contact Person: | Jolyn Tenllado
Regulatory Affairs Specialist | | Phone Number: | 314-731-8386 | | Fax Number: | 314-731-8689 | | Date of Preparation: | January 7, 2005 | | Device Name: | | | Formal/Trade Name: | VITEK® 2 Gram Positive Ertapenem (≤ 0.5 - ≥ 8 µg/ml) | | Classification Name: | Fully Automated Short-Term Incubation Cycle
Antimicrobial Susceptibility Device, 21
CFR 866.1645 | | Common Name: | VITEK 2 AST-GP Ertapenem | | Predicate Device: | VITEK 2 Gram Positive Susceptibility Test for
Gatifloxacin (K032788) | #### D. 510(k) Summary: B. ். VITEK® 2 Gram Positive Ertapenem is designed for antimicrobial susceptibility testing of Staphylococcus aureus (methicillin susceptible strains only), and Streptococcus agalactiae. It is intended for use with the VITEK 2 System as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. The antimicrobial presented in VITEK 2 AST Cards is in concentrations equivalent by efficacy to standard method concentrations in mcg/ml. The VITEK 2 AST Cards are essentially miniaturized versions of the doubling rily n technique for determining the minimum inhibitory concentration (MIC) microdilution methodology The bacterial isolate to be tested is diluted to a standardized concentration in 0.45% saline before being used to rehydrate the antimicrobial medium within the card. The VITEK 2 automatically fills, seals and places the card into the incubator/reader. The VITEK 2 monitors the growth of each well in the card over a defined period of time (up to 18 hours). At the completion of the incubation cycle, a report is generated that contains the MIC value along with the interpretive category result for each antibiotic contained on the card. {1}------------------------------------------------ 2 VITE:K 2 Gram Positive Ertapenem demonstrated substantially equivalent performance when VITER 2 Gram Positive Enapenen Gomondiation method, as defined in the FDA Class II compared with the NCCLS reference agar dilution method, as defined in ETDA Class II Compared with the NOOLO releirence agar unaron railaron rail Susceptibility Test (AST) Systems; Guidance for Industry and FDA. Issued Feb. 5, 2003. The Premarket Notification (510[k]) presents data in support of VTEK 2 Gram Positive The Premiation (QTo[N]) prosents used with fresh and stock clinical isock clinical isocates and stock challenge strains. The external evaluations were designed to confirm the acceptability Stock Challenge Straine: "The Skener by comparing its performance with the NCCLS again of VTEK 2 Gram Positive Extapenen by och positive Ertapenem demonstrated acceptable ulludion relerence mothou. "In Category Agreement when compared to the agar dilution penormance of 30.0% Overall Gategory Agrical demonstrated acceptable results. {2}------------------------------------------------ Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized caduceus symbol, which is a staff with two snakes entwined around it. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the caduceus symbol. The logo is black and white. Food and Drug Administration 2098 Gaither Road Rockville MD 20850 FEB 1 8 2005 Ms. Jolyn Tenllado Regulatory Affairs Specialist BioMérieux, Inc. 595 Anglum Road Hazelwood, MO 63042-2320 Re: k050076 R050070 Trade/Device Name: VITEK® Gram Positive Ertapenem (≤0.5 ->8 µg/ml) Regulation Number: 21 CFR 866.1645 Regulation Name: Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility Devices Regulatory Class: Class II Product Code: LON Dated: January 11, 2005 Received: January 12, 2005 Dear Ms. Tenllado: We have reviewed your Section 510(k) premarket notification of intent to market the device wt have reviewed your becamed the device is substantially equivalent (for the indications forchenout above and harsure) to legally marketed predicate devices marketed in interstate for use stated in the encround) to the enactment date of the Medical Device Amendments, or to conninered pror to they 2011 and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The r va may, mererere, mains of the Act include requirements for annual registration, listing of general controll provider ing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device it may be subject to Saten additions (CFR), Parts 800 to 895. In addition, FDA can ou lound further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean r lease be actived that i British that your device complies with other requirements of the Act that I 197 has Interes and regulations administered by other Federal agencies. You must of any I catales and registments, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice e FR Part 807), tabelies in the quality systems (QS) regulation (21 CFR Part 820). {3}------------------------------------------------ Page 2 - This letter will allow you to begin marketing your device as described in your Section 5 10(k) 1978 to the more of the success of the same of your device to a legal I his letter will anow you to ocgin maketing your antial equivalence of your device to a legally premarket notification. The FDA finding of substantial equivales and thus, p premarket notification. "The PDF Intamg er oussions for your device and thus, permits your device to proceed to the market. If you desire specific information about the application of labeling requirements to your device, of Jr If you desire specific information actually of your device, please contact the Office of In or questions on the promotion and advertising of your and any and any and any and of questions on the promotion and Safety at (240)276-0484. Also, please note the V IITO Diagnostic Device Devilation and reach and the motification" (21CFR Part 807.97). regulation entitled, "Misolanding of Torento on your responsibilities under the Act from the You may other other general informational and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html Sincerely yours, Sales, a For Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ # Indications for Use 510(k) Number (if known):_K 0500 74 Device Name: VITEK® 2 Gram Positive Ertapenem (≤0.5 - >8 µg/ml) Indications For Use: The VITEK® 2 Antimicrobial Susceptibility Test (AST) is intended to be used with the The VITER 2 System for the automated quantitative or qualitative susceptibility testing of isolated colonies for the most clinically significant aerobic gram-negative bacilli, Isolated occus spp., Enterococcus spp., Streptococcus agalactiae, and S. pneumoniae. prited on and Positive Ertapenem is designed for antimicrobial susceptibility testing of Staphylococcus aureus (methicillin susceptible strains only), and Streptococcus Staphylococcas auread (motholiin CErtapenem is a qualitative test. It is intended for use with the VITEK 2 System as a laboratory aid in the determination of in vitro susceptibility to antimicrobial agents. Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Division Sign-Off Car of In Vitro Diagnostic De t in manon and Safety Page 1 of 1 KOSODTL 510(k)_ --- **Source:** [https://fda.innolitics.com/submissions/MI/subpart-b%E2%80%94diagnostic-devices/LON/K050076](https://fda.innolitics.com/submissions/MI/subpart-b%E2%80%94diagnostic-devices/LON/K050076) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com